PWA
NBIX icon

Principia Wealth Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Principia Wealth Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$674 Buy
4
+2
+100% +$297 ﹤0.01% 840
2026
Q1 		$263 Buy
2
+1
+100% +$133 ﹤0.01% 931
2025
Q4 		$142 Hold
1
– – ﹤0.01% 949
2025
Q3 		$140 Hold
1
– – ﹤0.01% 907
2025
Q2 		$126 Sell
1
-1
-50% -$115 ﹤0.01% 907
2025
Q1 		$191 Sell
2
-3
-60% -$380 ﹤0.01% 776
2024
Q4 		$683 Buy
+5
New +$618 ﹤0.01% 451

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Principia Wealth Advisory's NBIX Position: Q2 2026 in Review

Principia Wealth Advisory increased its Neurocrine Biosciences (NBIX) stake by 100% in Q2 2026, buying an estimated $297 and bringing the position to 4 shares worth $674. The position accounts for ﹤0.01% of the portfolio, ranked #840.

Principia Wealth Advisory first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $683 in Q4 2024. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Principia Wealth Advisory held 4 shares of Neurocrine Biosciences worth $674 as of Q2 2026.
  • Principia Wealth Advisory bought 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #840 holding.
  • Principia Wealth Advisory first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Principia Wealth Advisory's Neurocrine Biosciences position peaked at $683 in Q4 2024.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.